Characteristics of patients
| . | Group . | All (n = 222) . | ||||
|---|---|---|---|---|---|---|
| R-ACVBP 14 (n = 114) . | R-CHOP 14 (n = 108) . | |||||
| N . | % . | N . | % . | N . | % . | |
| Sex | ||||||
| Male | 64 | 56 | 67 | 62 | 131 | 59 |
| Female | 50 | 44 | 41 | 38 | 91 | 41 |
| Age, years | ||||||
| Median (range) | 47 (19-59) | 44 (18-59) | 46 (18-59) | |||
| Performance status | ||||||
| <2 | 90 | 79 | 74 | 69 | 164 | 74 |
| ≥2 | 24 | 21 | 34 | 31 | 58 | 26 |
| Ann Arbor stage | ||||||
| I-II | 0 | 0 | 7 | 6 | 7 | 3 |
| III-IV | 114 | 100 | 101 | 94 | 215 | 97 |
| Lactate dehydrogenase | ||||||
| ≤Normal | 7 | 6 | 5 | 5 | 12 | 5 |
| >Normal | 107 | 94 | 103 | 95 | 210 | 95 |
| Age-adjusted IPI | ||||||
| 1 | 4 | 4 | 2 | 2 | 6 | 3 |
| 2 | 89 | 78 | 82 | 76 | 171 | 77 |
| 3 | 21 | 18 | 24 | 22 | 45 | 20 |
| Nb of extranodal sites | ||||||
| ≤1 | 44 | 39 | 33 | 31 | 77 | 35 |
| >1 | 70 | 61 | 75 | 69 | 145 | 65 |
| Mass >10 cm | ||||||
| Yes | 25 | 22 | 30 | 28 | 55 | 25 |
| No | 89 | 78 | 77 | 72 | 166 | 75 |
| B symptoms | ||||||
| Yes | 60 | 53 | 52 | 48 | 112 | 50 |
| No | 54 | 47 | 56 | 52 | 110 | 50 |
| BM involvement | ||||||
| Not involved | 85 | 75 | 82 | 76 | 167 | 75 |
| Involved | 20 | 18 | 21 | 19 | 41 | 18 |
| Unspecified | 4 | 4 | 2 | 2 | 6 | 3 |
| Not done | 5 | 4 | 3 | 3 | 8 | 4 |
| Pathology review | 99 | 87 | 101 | 93 | 200 | 90 |
| DLBCL | 81 | 82 | 79 | 78 | 160 | 80 |
| Primary mediastinal B cell | ||||||
| Lymphoma | 16 | 16 | 18 | 18 | 34 | 17 |
| Follicular lymphoma | 1 | 1 | 0 | 1 | 0.5 | |
| Mantel cell lymphoma | 1 | 1 | 1 | 1 | 2 | 1 |
| Burkitt lymphoma | 0 | 1 | 1 | 1 | 0.5 | |
| Other | 0 | 2 | 2 | 2 | 1 | |
| . | Group . | All (n = 222) . | ||||
|---|---|---|---|---|---|---|
| R-ACVBP 14 (n = 114) . | R-CHOP 14 (n = 108) . | |||||
| N . | % . | N . | % . | N . | % . | |
| Sex | ||||||
| Male | 64 | 56 | 67 | 62 | 131 | 59 |
| Female | 50 | 44 | 41 | 38 | 91 | 41 |
| Age, years | ||||||
| Median (range) | 47 (19-59) | 44 (18-59) | 46 (18-59) | |||
| Performance status | ||||||
| <2 | 90 | 79 | 74 | 69 | 164 | 74 |
| ≥2 | 24 | 21 | 34 | 31 | 58 | 26 |
| Ann Arbor stage | ||||||
| I-II | 0 | 0 | 7 | 6 | 7 | 3 |
| III-IV | 114 | 100 | 101 | 94 | 215 | 97 |
| Lactate dehydrogenase | ||||||
| ≤Normal | 7 | 6 | 5 | 5 | 12 | 5 |
| >Normal | 107 | 94 | 103 | 95 | 210 | 95 |
| Age-adjusted IPI | ||||||
| 1 | 4 | 4 | 2 | 2 | 6 | 3 |
| 2 | 89 | 78 | 82 | 76 | 171 | 77 |
| 3 | 21 | 18 | 24 | 22 | 45 | 20 |
| Nb of extranodal sites | ||||||
| ≤1 | 44 | 39 | 33 | 31 | 77 | 35 |
| >1 | 70 | 61 | 75 | 69 | 145 | 65 |
| Mass >10 cm | ||||||
| Yes | 25 | 22 | 30 | 28 | 55 | 25 |
| No | 89 | 78 | 77 | 72 | 166 | 75 |
| B symptoms | ||||||
| Yes | 60 | 53 | 52 | 48 | 112 | 50 |
| No | 54 | 47 | 56 | 52 | 110 | 50 |
| BM involvement | ||||||
| Not involved | 85 | 75 | 82 | 76 | 167 | 75 |
| Involved | 20 | 18 | 21 | 19 | 41 | 18 |
| Unspecified | 4 | 4 | 2 | 2 | 6 | 3 |
| Not done | 5 | 4 | 3 | 3 | 8 | 4 |
| Pathology review | 99 | 87 | 101 | 93 | 200 | 90 |
| DLBCL | 81 | 82 | 79 | 78 | 160 | 80 |
| Primary mediastinal B cell | ||||||
| Lymphoma | 16 | 16 | 18 | 18 | 34 | 17 |
| Follicular lymphoma | 1 | 1 | 0 | 1 | 0.5 | |
| Mantel cell lymphoma | 1 | 1 | 1 | 1 | 2 | 1 |
| Burkitt lymphoma | 0 | 1 | 1 | 1 | 0.5 | |
| Other | 0 | 2 | 2 | 2 | 1 | |
BM, bone marrow; Nb, number.